Latest Conference Articles

Deep Dive into a Case Study on Liver-Sparing TBI Plus Helical Tomotherapy in Relapsed Pre-B Cell ALL

A case study of a patient with pre-B cell acute lymphoblastic leukemia showed helical tomotherapy with IMRT-based TBI is a viable option for organ sparing.

Navigating Career Crossroads: Insights from Hope Rugo’s Journey as a Woman in Oncology

Hope S. Rugo, MD, draws on her own journey as a woman in oncology to provide insights on navigating career transitions and building support networks.

Graff Highlights the Importance of Perseverance and Self-Advocacy as a Woman in Oncology

Stephanie L. Graff, MD, shares her journey to becoming an oncologist, advice for work-life balance, and ways to confront gender bias in medicine.

QOL Remains a Key Goal of the Use of Radiation in Rectal Cancer

Nina Sanford, MD, discusses how radiation could help improve QOL for patients with rectal cancer and situations when radiation or surgery could be omitted.

Retrospective Study Shows Neoadjuvant SCRT is Associated With Optimal Surgical Outcomes in Rectal Cancer

Prolonged duration from neoadjuvant SCRT to surgery did not increase the risk of poor mesorectum specimen quality or post-operative morbidity in rectal cancer.

Dr Singh on the Utility of Radiation Therapy in Lung Cancer

Raj Singh, MD, discusses radiation therapy in patients with metastatic lung cancer, highlighting the evolution of treatment within this landscape.

Dr Franco on the Integration of Immunotherapy Treatment in Endometrial Cancer

Idalid Franco, MD, MPH, discusses the use of radiation therapy and immunomodulatory agents in the treatment of endometrial cancer.

Brown Details the Evolving Role of PCI and HA-PCI in Small Cell Lung Cancer

Paul D. Brown, MD, gives a history of prophylactic cranial irradiation in small cell lung cancer and describes its standing in the treatment paradigm.

Dr Zhang on Topics of Ongoing Debate Within Prostate Cancer

Tian Zhang, MD, MHS, discusses areas of ongoing debate regarding prostate cancer management.

TNO155 Plus Spartalizumab or Ribociclib Elicits Disease Control, Is Safe in Advanced Solid Tumors

TNO155 plus spartalizumab or ribociclib was well tolerated and demonstrated disease control in patients with advanced solid tumors.

Dr Graff on the Trajectory of Her Career in Breast Cancer

Stephanie L. Graff, MD, discusses the trajectory of her career growth in breast oncology and explains how different factors can play a role in an oncologist’s career path.

Dr Rugo on Challenges Faced as a Woman in Oncology

Hope S. Rugo, MD, discusses challenges that women face in the workplace in oncology care.

Targeted Delivery of IL-12 Shows Preliminary Antitumor Activity in Advanced Solid Tumors

A high proportion of patients with metastatic solid tumors experienced stable disease following treatment with the immunocytokine in the DODEKA trial.

Dr Shore on Key Clinical Trial Data in Biochemically Recurrent Prostate Cancer

Neal Shore, MD, FACS, discusses findings from clinical trials in patients with prostate cancer who experience biochemical recurrence.

Dr Hussain on Key Ongoing Clinical Trials in Metastatic Castrate-Resistant Prostate Cancer

Maha Hussain, MD, FACP, FASCO, discusses clinical trials evaluating therapeutics for patients with metastatic castrate-resistant prostate cancer.

MRD Testing Presents Challenges and Opportunities in Breast Cancer Care

Heather McArthur, MD, MPH, discusses the prognostic benefits of circulating tumor DNA and limitations that prevent these results from being predictive.

Dr Tripathy on the Management of Early-Stage HER2+ Breast Cancer

Debu Tripathy, MD, discusses current considerations for the management of early-stage HER2-positive breast cancer.

Dr Bochner on Key Points for Community Oncologists in the Management of Muscle-Invasive Bladder Cancer

Bernard H. Bochner, MD, FACS, discusses considerations for community oncologists when treating patients with muscle-invasive bladder cancer.

Dr Xu on Treatment Sequencing Considerations in Metastatic Renal Cell Carcinoma

Wenxin (Vincent) Xu, MD, discusses the factors he takes into account when sequencing treatment options for patients with metastatic renal cell carcinoma.

Dr Rugo on the Evolution of ADCs in HR+/HER2+ and HER2-Low Breast Cancer

Hope Rugo, MD, discusses the evolution of antibody-drug conjugates in hormone receptor–positive, HER2-positive, and HER2-low breast cancer.

Artificial Intelligence in Prostate Cancer Pathology: Friend or Foe?

Peter A. Humphrey, MD, PhD, presents on the standing of artificial intelligence in prostate cancer pathology.

Targeted Agents Expand the HR+/HER2– Metastatic Breast Cancer Treatment Arena

Erica Stringer-Reasor, MD, highlights the evolution of therapies for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Dr Huppert on Data Informing the Sequence of Systemic Therapy in Early-Stage TNBC

Laura A. Huppert, MD, discusses data informing the sequence of immunotherapy and chemotherapy regimens in early-stage triple-negative breast cancer.

Piecing the Puzzle Together: Treatment After Progression in Metastatic Castration-Resistant Prostate Cancer

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution.

Dr Tagawa on the Role of PARP Inhibitors in Prostate Cancer Treatment

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the standing of PARP inhibitors in the treatment paradigm of metastatic castration-resistant prostate cancer.

Dr Dreicer on Improving Clinical Trial Design in Prostate Cancer

Robert Dreicer, MD, discusses the shortcomings of current clinical trials in prostate cancer and what he sees as the biggest area of improvement.

Neoadjuvant Chemotherapy Has Led to De-Escalation of Breast Cancer Surgery and Radiation

Terry P. Mamounas, MD, MPH, FACS, discusses treatment options after neoadjuvant chemotherapy and how neoadjuvant chemotherapy influences axillary surgery.

PRMT5 Inhibitors Plus Antiestrogens May Combat Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer

PRMT5 inhibitors with antiestrogens represents a therapeutic strategy that may overcome resistance to CDK4/6 inhibitors in ER+/RB-deficient breast cancer.

ADCs Serve as “Exciting and Effective Drug Delivery System” in HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO, shares progress made with ADCs and the interest in moving these agents up in the HR-positive/HER2-negative breast cancer paradigm.

Racial Disparities Magnified in Cardiac Dose, Toxicity Differences With RT for Breast Cancer

Racial and ethnic disparities for mortality are present in breast cancer, especially as it relates to radiation therapy toxicity and cardiac dose.